Drug WatchHepatitis C and Compensated Cirrhosis Drug Approved for Eight-Week TreatmentAschenbrenner, Diane S. MS, RNAuthor Information Diane S. Aschenbrenner is an assistant professor at Notre Dame of Maryland University in Baltimore. She also coordinates Drug Watch: firstname.lastname@example.org. AJN, American Journal of Nursing: January 2020 - Volume 120 - Issue 1 - p 24-25 doi: 10.1097/01.NAJ.0000652004.90791.e9 Buy Metrics Abstract The antiviral combination drug Mavyret (glecaprevir–pibrentasvir), used to treat patients with hepatitis C virus and compensated cirrhosis, is now approved for a treatment duration of eight weeks in treatment-naive adult and pediatric patients. Changes to the product's labeling regarding the shortened length of therapy are based on preliminary data from the EXPEDITION-8 trial. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.